Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 5/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CFB | P00751 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873153 | 0.85 | IMPDH2 (0.42) | PIN1PKN1PKN2CSNK1DCSNK1G2 | |
| SCHEMBL207168 | 0.71 | ALDH1A1 (0.44) | METAP2METAP1NOS1GRIN1GRIN2B | |
| SCHEMBL207131 | 0.71 | ALPL (0.41) | METAP2METAP1 | |
| SCHEMBL10468270 | 0.69 | PGK1 (0.41) | — | |
| SCHEMBL29424823 | 0.68 | PRKCI (0.53) | PIN1PKN1PKN2METAP2METAP1 | |
| SCHEMBL11134 | 0.68 | PRKCI (0.53) | PIN1PKN1PKN2METAP2METAP1 | |
| SCHEMBL7773268 | 0.68 | PIN1 (0.45) | PIN1PKN1PKN2CSNK1DCSNK1G2 | |
| SCHEMBL1917623 | 0.67 | MMP12 (0.51) | — | |
| SCHEMBL7623293 | 0.67 | — | — | |
| SCHEMBL1246822 | 0.67 | NPBWR1 (0.44) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197872-A1 | PHENYLISOQUINOLINE AND PHENYLQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Novartis Ag (CH) | 2010-06-23 | — | — | EP | disclosed |
| US-20090074791-A1 | Phenylisoquinoline and Phenylquinazoline Derivatives | BEERLI RENE | 2009-03-19 | — | — | US | disclosed |
| WO-2009027475-A1 | PHENYLISOQUINOLINE AND PHENYLQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | NOVARTIS AG (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074791-A1 | Phenylisoquinoline and Phenylquinazoline Derivatives | CAMK1D, CAMK1, PHPT1 | PIN1 965/4885PKN1 1412/4885PKN2 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.